PRIME, the European Medicines Agency’s (EMA) Priority Medicines (or PRIME) scheme, is a regulatory tool designed to support medicines that address unmet medical needs. For academic researchers and small development teams, using PRIME in drug development can offer significant advantages, particularly in rare diseases where resources are tight.
About 7,000 rare diseases are currently identified. Only around 5% have an effective treatment available. Every tool that reduces costs, shortens timelines, or improves the chance of reaching patients deserves serious attention. But PRIME is not a solution for every project. Applied at the right moment and with the right foundation, it can deliver significant gains.
This article explains what PRIME offers, where its limitations bite, and what strategic choices make the difference.
What PRIME essentially provides
The core benefit of PRIME in drug development is access to the EMA. Specifically, early and enhanced scientific dialogue with the EMA’s Committee for Medicinal Products for Human Use (CHMP) or the Committee for Advanced Therapies (CAT).
Under PRIME the EMA appoints a dedicated rapporteur early in development. That relationship provides a consistent point of contact to discuss relevant aspects of the future Marketing Authorisation Application. Kick-off meetings allow development teams to align plans with EMA expectations before significant investment is committed, not after.
PRIME also increases flexibility around scientific advice. Timelines for advice may be shortened, and other stakeholders such as Health Technology Assessment (HTA) bodies may be involved earlier. For small teams and academic spin-offs with limited regulatory experience, the submission readiness meeting is particularly valuable. It covers dossier maturity, regulatory strategy, and potential challenges before the marketing authorisation application is submitted.
PRIME also enables eligibility for accelerated assessment of the marketing authorisation, which can really shorten the time to approval. One important clarification: PRIME carries no financial incentive. Fees remain the same. The value is entirely in access, dialogue, and speed. The benefit of this earlier and broader access is the avoidance of delays that would otherwise surface late in development, when they are most expensive to fix.
Where PRIME falls short
Understanding the limitations of PRIME in drug development is as important as understanding its benefits.
The rejection rate is high. Only around 26% of applications are accepted. The eligibility bar is demanding: a medicine must demonstrate the potential to address an unmet medical need to a significant extent. For rare diseases with very small patient populations, generating robust clinical evidence of that significance is genuinely difficult.
Timing is critical. Applying too early, before sufficient evidence exists, leads to rejection. Applying too late limits the practical benefit of EMA dialogue and may also lead to rejection. The window is narrower than many applicants expect.
The quality of the application also matters. A poorly articulated unmet medical need argument will harm a PRIME application just as surely as weak scientific data. Precision and clarity in how the case is presented is a critical success factor.
Substantive requirements or decision making processes are not affected by PRIME. It accelerates regulatory approval but has no influence over HTA or reimbursement decisions at national level. A programme that satisfies EMA requirements may still face HTA bottlenecks that delay patient access by months or years after approval. This step is frequently overlooked, and the consequences for patients can be significant.
Finally, PRIME does not fix a flawed development plan. Early dialogue with EMA will increase t he chance that any issues surface earlier, but it will not resolve them. A credible and complete development plan covering clinical strategy, CMC, and nonclinical package is a prerequisite, not a follow-up.
How to use PRIME in drug development strategically
The decision to pursue PRIME should follow from programme design, not precede it.
Build the evidence base first. Robust nonclinical data in the relevant disease model, combined with exploratory clinical data establishing proof of concept, strengthens both the PRIME application and the development plan itself. For some projects, academia and SMEs may be eligible for EMA’s Early Entry PRIME programme if preclinical data is strong enough.
Time the application carefully. Apply when the benefit-risk profile clearly demonstrates significance, but early enough for EMA dialogue to meaningfully shape the development programme. Too early, the case cannot be made. Too late, the benefit diminishes.
Combine PRIME with an Orphan Drug Designation (ODD) where applicable. An ODD brings incentives PRIME does not offer, including market exclusivity and fee reductions. The two designations are complementary. ODD applications are typically submitted earlier in development, and an already granted ODD may have a positive impact during PRIME eligibility evaluation.
Consider EMA scientific advice before applying. Scientific advice clarifies requirements, identifies gaps, and strengthens the PRIME application. It remains valuable even if PRIME is ultimately not pursued.
Keep the development plan realistic and complete. PRIME provides dialogue, not rescue. A PRIME application should come alongside a credible development plan, not instead of one.
The Bigger Picture
Using PRIME in drug development is most effective when it sits within a broader strategy. Regulatory dialogue alone does not get a medicine to patients. It needs to be combined with a realistic funding mix, a well-structured consortium, and governance that keeps patient access central throughout development.
For rare disease programmes with the right scientific foundation, PRIME can shorten timelines, provide guidance, indirectly reduce costs, and support the development of medicines that reach patients at a sustainable price. That is what socially responsible drug development ultimately requires.
If you are exploring whether PRIME is relevant for your project, or whether your development plan is ready to support an application, we are always open to a conversation.
